Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.

Saved in:
Bibliographic Details
Title: Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.
Authors: Sweiss K; University of Illinois at Chicago, Chicago, Illinois. Electronic address: ksweis2@uic.edu., Wagner C; Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Anto E; Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Greene T; Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Sun R; University of Illinois at Chicago, Chicago, Illinois., Gonzalez R; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Puglianini OC; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Freeman C; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Ionescu F; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Patel K; The University of Texas MD Anderson Cancer Center, Houston, Texas., Ferreri C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Gaballa M; The University of Texas MD Anderson Cancer Center, Houston, Texas., Shune L; The University of Kansas Medical Center, Kansas City, Kansas., McGuirk J; The University of Kansas Medical Center, Kansas City, Kansas., Sidana S; Stanford University, Palo Alto, California., Hovanky V; Stanford University, Palo Alto, California., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Raza S; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Anwer F; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Hashmi H; Medical University of South Carolina, Charleston, South Carolina., Davis J; Medical University of South Carolina, Charleston, South Carolina., Afrough A; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Hematologic Malignancies and Cellular Therapy Program, Dallas, Texas., Kaur G; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Hematologic Malignancies and Cellular Therapy Program, Dallas, Texas., Anderson L Jr; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Hematologic Malignancies and Cellular Therapy Program, Dallas, Texas., Forsberg P; UC Health Blood Disorders and Cell Therapies Center, Aurora, Colorado., Herr M; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Hansen DK; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Hakan Kocoglu M; University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center, Baltimore, Maryland., Sborov D; Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Source: Transplantation and cellular therapy [Transplant Cell Ther] 2025 Dec; Vol. 31 (12), pp. 989-999. Date of Electronic Publication: 2025 Sep 17.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-6367
DOI:10.1016/j.jtct.2025.08.015